



## MEDICAL SURGICAL VISION CLINICAL PROTOCOL

<b>POLICY TITLE</b>	<b>Intravitreal anti-VEGF/Biologic Injections</b>		
<b>CATEGORY</b>	Medical Surgical	<b>POLICY ID NUMBER</b>	300_NYS_HF_v3
<b>ORIGINAL EFFECTIVE DATE</b>	01/01/2025	<b>LAST REVIEW DATE</b>	09/05/2024
<b>LAST APPROVAL DATE</b>	04/28/2025	<b>LAST REVISION DATE</b>	03/04/2025
<b>EXCLUSIONS</b>	<b>Applicable to Health First Programs in New York State only.</b>		

### DISCLAIMER

CPT® Codes, Descriptors, and other data are copyright 2025 American Medical Association (or such other date of publication of CPT®). All Rights Reserved to AMA. Additional resources include CMS Medicare Provider Guidelines @ CMS.gov. This information may not be sold, licensed, or unlawfully used and is intellectual property of EyeMed and the aforementioned entities.

### Applicable Codes:

#### **J0177** EYLEA HD (Aflibercept HD) injection – intravitreal injection

*Aflibercept HD is a vascular endothelial growth factor (VEGF) inhibitor used for intravitreal injection*

#### **J0178** EYLEA (aflibercept) injection- intravitreal injection

*Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration.*

#### **J0179** BEOVU (brolucizumab-dbl) ) injection-intravitreal injection

*Brolucizumab-dbl is a human vascular endothelial growth factor (VEGF) inhibitor used as an intravitreal injection.*

#### **J2777** VABYSMO (faricimab-svoa) injection-intravitreal injection

*Faricimab-SVOA is a vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor.*

#### **J2778** LUCENTIS (ranibizumab) injection-intravitreal injection

*Ranibizumab, a recombinant humanized immunoglobulin G, kappa monoclonal antibody fragment, is a vascular endothelial growth factor A (VEGF-A) antagonist used as an intravitreal injection.*

# 1 Indication and Limitations<sup>1</sup>

## 1.1 Medical Necessity

- 1.1.1 Ocular Coherence Tomography (OCT) and/or fluorescein angiography (FA) test results must be interpreted and firmly establish/support diagnosis
- 1.1.2 Appropriate diagnosis and clinical findings must be well-documented to support medical necessity
  - 1.1.2.1 Secondary CNV or unlisted diagnosis may be submitted for prior authorization after Avastin trial failure, and all necessary criteria are satisfied.
    - 1.1.2.1.1 Claims will be reviewed on a case-by-case basis.

## 1.2 Additional Requirements (applicable for all codes)

- 1.2.1 Procedure note must include:
  - 1.2.1.1 Actual administered drug, dosage, injection site, & route of administration
  - 1.2.1.2 Injection lot # & expiration date
  - 1.2.1.3 Post-injection vision check  $\geq$  CF
  - 1.2.1.4 Specific notation patient has been queried/screened for contraindicating/ co-morbidities.
- 1.2.2 Avastin trial failure must clearly be indicated in chart
  - 1.2.2.1 Does not apply to new members who are currently on successful intravitreal injection treatment
  - 1.2.2.2 Minimum Avastin treatment trial consisting of 3 Avastin (bevacizumab) injections
  - 1.2.2.3 Inadequate clinical response
    - 1.2.2.3.1 Fewer than 3 lines of improvement on visual acuity testing
  - 1.2.2.4 Medical necessity reason for changing therapy from Avastin to one of the above-listed drugs.
- 1.2.3 Informed consent stating all pertinent risks must include:
  - 1.2.3.1 Date, consent to perform/waive, patient or representative signature, surgeon/physician signature, and witness signature
- 1.2.4 Authorization Time frame
  - 1.2.4.1 will be given for the time period of 12 months
  - 1.2.4.2 will cover up to the listed maximum of injections during the time period.
  - 1.2.4.3 Additional requested injections will be subject to review
    - 1.2.4.3.1 determinations will be made on a case-by-case basis and subject to medical necessity.
- 1.2.5 Services should be performed as indicated by current medical literature and/ or standards of practice.
- 1.2.6 When services are performed in excess of established parameters, they may be subject to review for medical necessity.
- 1.2.7 Medicare Advantage and step therapy for Part B drugs (**§ 422.136**)
  - 1.2.7.1 Apply step therapy only to new administration of Part B drugs using at least a 365-day lookback period

## 2 Eylea HD

### 2.1 Treatment indications with approved dosage schedule - (supporting ICD-10 pages 9-13):

#### 2.1.1 Neovascular (Wet) age-related macular degeneration (nAMD)

##### 2.1.1.1 Recommended dose

**2.1.1.1.1** 8 mg (0.07 mL of 114.3 mg/mL solution)

**2.1.1.1.2** administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses,

**2.1.1.1.3** followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week.

#### 2.1.2 Diabetic macular edema (DME)

##### 2.1.2.1 Recommended dose

**2.1.2.1.1** 8 mg (0.07 mL of 114.3 mg/mL solution)

**2.1.2.1.2** administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses,

**2.1.2.1.3** followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 16 weeks, +/- 1 week

#### 2.1.3 Diabetic retinopathy (DR)

##### 2.1.3.1 Recommended dose

**2.1.3.1.1** 8 mg (0.07 mL of 114.3 mg/mL solution)

**2.1.3.1.2** administered by intravitreal injection every 4 weeks (approximately every 28 days +/- 7 days) for the first three doses

**2.1.3.1.3** followed by 8 mg (0.07 mL of 114.3 mg/mL solution) via intravitreal injection once every 8 to 12 weeks, +/- 1 week.

## 3 Eylea

### 3.1 Treatment indications with approved dosage schedule - (supporting ICD-10 pages 5-8):

#### 3.1.1 Neovascular (Wet) age-related macular degeneration (AMD)

##### 3.1.1.1 Recommended dose

**3.1.1.1.1** (2) milligrams

**3.1.1.1.2** administered by intravitreal injection once every 4 weeks (monthly) for the first 12 weeks (3 months),

**3.1.1.1.3** THEN 2 milligrams administered by intravitreal injection once every 8 weeks [2 months]

---

<sup>1</sup> Physician attests at time of request submission that physician signed documentation across the full timeframe of treatment rendered (chart, procedures, order, testing interpretation) supports all indications and limitations for service based on this policy and industry billing guidance.

- 3.1.1.1.4 Although EYLEA (aflibercept) may be dosed as frequently as 2 milligrams every 4 weeks (monthly), additional efficacy was not demonstrated when EYLEA (aflibercept) was dosed every 4 weeks as compared to every 8 weeks.
    - 3.1.1.1.5 Some patients may require monthly injections after the initial 3-month period
    - Utilization Guidelines
    - 3.1.1.1.6 Max injections per calendar year = 16
- 3.1.2 Diabetic macular edema (DME) & Diabetic Retinopathy (DR)
  - 3.1.2.1 Recommended dose
    - 3.1.2.1.1 (2) milligrams
    - 3.1.2.1.2 administered by intravitreal injection once every 4 weeks (monthly)(approximately 28 days) for the first 5 injections
    - 3.1.2.1.3 THEN 2 milligrams administered by intravitreal injection once every 8 weeks [2 months]
    - 3.1.2.1.4 Some patients may require monthly injections after the initial 5-month period
- 3.1.3 Macular Edema Following Retinal Vein Occlusion (RVO)
  - 3.1.3.1 Recommended dose
    - 3.1.3.1.1 (2) milligrams
    - 3.1.3.1.2 administered by intravitreal injection once every 4 weeks (monthly) (approximately 25 days)
- 3.1.4 Retinopathy of Prematurity (ROP)
  - 3.1.4.1 Recommended dose
    - 3.1.4.1.1 0.4 milligrams (0.01 mL or 10 microliters of 40 mg/mL solution)
    - 3.1.4.1.2 administered by intravitreal injection once every 4 weeks (monthly)(administered by intravitreal injection
    - 3.1.4.1.3 may be given bilaterally on the same day
    - 3.1.4.1.4 Injections may be repeated in each eye
    - 3.1.4.1.5 Treatment interval between doses injected into the same eye should be at least 10 days

## 4 Beovu

### 4.1 Treatment indications with approved dosage schedule (supporting ICD-10 pages 13):

- 4.1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  - 4.1.1.1 Recommended dose
    - 4.1.1.1.1 6 milligrams (0.05 mL of 120 mg/mL solution)
    - 4.1.1.1.2 Administered by intravitreal injection monthly (approximately every 25-31 days) for the first three doses,
    - 4.1.1.1.3 followed by one dose of 6 milligrams (0.05 mL) every 8-12 weeks
  - 4.1.1.2 Utilization Guidelines

**4.1.1.2.1** Max injections per calendar year = 16

**4.1.2** Diabetic Macular Edema (DME)

**4.1.2.1** Recommended dose

**4.1.2.1.1** (6) milligrams (0.05 mL of 120 mg/mL solution)

**4.1.2.1.2** Administered by intravitreal injection every six weeks (approximately every 39-45 days) for the first five doses,

**4.1.2.1.3** followed by one dose of 6 milligrams (0.05 mL of 120 mg/mL solution) every 8-12 weeks

**4.1.2.2** Utilization Guidelines

**4.1.2.2.1** Max injections per calendar year = 16

## **5 Vabysmo**

### **5.1 Treatment indications with approved dosage schedule (supporting ICD-10 pages 17-18)**

**5.1.1** Neovascular (Wet) Age-Related Macular Degeneration (nAMD)

**5.1.1.1** Recommended dosage

**5.1.1.1.1** 6 mg (0.05 mL of 120 mg/mL solution)

**5.1.1.1.2** administered by intravitreal injection every 4 weeks (approximately every  $28 \pm 7$  days, monthly) for the first 4 doses, then

**5.1.1.1.3** followed by optical coherence tomography and visual acuity evaluations 8 and 12 weeks later to inform whether to give a 6 mg dose via intravitreal injection on one of the following three regimens: 1) Weeks 28 and 44; 2) Weeks 24, 36 and 48; or 3) Weeks 20, 28, 36 and 44.

**5.1.1.1.4** Although additional efficacy was not demonstrated in most patients when VABYSMO was dosed every 4 weeks compared to every 8 weeks,

**5.1.1.1.5** some patients may need every 4-week (monthly) dosing after the first 4 doses. Patients should be assessed regularly.

**5.1.2** Diabetic Macular Edema (DME)

**5.1.2.1** Recommended dosage

**5.1.2.1.1** 6 mg (0.05 mL of 120 mg/mL solution)

**5.1.2.1.2** administered by intravitreal injection every 4 weeks (approximately every 28 days  $\pm 7$  days, monthly) for at least 4 doses.

**5.1.2.1.3** If after at least 4 doses, resolution of edema based on the central subfield thickness (CST) of the macula as measured by optical coherence tomography is achieved, then the interval of dosing may be modified by extensions of up to 4 week interval increments or reductions of up to 8 week interval increments based on CST and visual acuity evaluations; OR

**5.1.2.1.4** injection can occur every 4 weeks for the first 6 doses, followed by 6 mg dose via intravitreal injection at intervals of every 8 weeks (2 months).

**5.1.2.1.5** Although additional efficacy was not demonstrated in most patients when VABYSMO was dosed every 4 weeks compared to every 8 weeks, some patients may need every 4 week (monthly) dosing after the first 4 doses. Patients should be assessed regularly.

**5.1.2.2** Utilization Guidelines

**5.1.2.2.1** Maximum injections per calendar year = 16

**5.1.2.2.2** Dosing more frequent than maximum is approved at plan discretion

## **6 Lucentis**

### **6.1 Treatment indication with approved dosage schedule (supporting ICD-10 pages 13-17):**

#### **6.1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD)**

##### **6.1.1.1 Recommended dosage**

**6.1.1.1.1** 0.5 milligrams (0.05 mL of 10 mg/mL solution)

**6.1.1.1.2** Administered by intravitreal injection once a month (approximately 28 days)

**6.1.1.1.3** Although not as effective, patients may be treated with 3 monthly doses followed by less frequent dosing with regular assessment.

**6.1.1.1.4** Although not as effective, patients may also be treated with one dose every 3 months after 4 monthly doses.

**6.1.1.1.5** Patients should be assessed regularly.

##### **6.1.1.2 Utilization Guidelines**

**6.1.1.2.1** Maximum injections per calendar year = 26

#### **6.1.2 Macular Edema Following Retinal Vein Occlusion (RVO)**

##### **6.1.2.1 Recommended dosage**

**6.1.2.1.1** 0.5 milligrams (0.05 mL of 10 mg/mL solution)

**6.1.2.1.2** administered by intravitreal injection once a month (approximately 28 days)

##### **6.1.2.2 Utilization Guidelines**

**6.1.2.2.1** Maximum injections per calendar year = 26

#### **6.1.3 Diabetic Macular Edema (DME) and Diabetic Retinopathy (DR)**

##### **6.1.3.1 Recommended dosage**

**6.1.3.1.1** 0.3 milligrams (0.05 mL of 6 mg/mL solution)

**6.1.3.1.2** administered by intravitreal injection once a month (approximately 28 days)

##### **6.1.3.2 Utilization Guidelines**

**6.1.3.2.1** Maximum injections per calendar year = 26

#### **6.1.4 Myopic Choroidal Neovascularization (mCNV)**

##### **6.1.4.1 Recommended dosage**

**6.1.4.1.1** 0.5 mg (0.05 mL of 10 mg/mL solution) administered by intravitreal injection once a month (approximately 28 days) for up to three months.

**6.1.4.1.2** Patients may be retreated if needed

#### **6.1.4.2** Utilization Guidelines

**6.1.4.2.1** Max injections per calendar year = 8

## 7 Supporting Diagnoses

### 7.1 EYLEA (aflibercept) injection- intravitreal injection listed as Group 2 on LCD article

E08.311	Diabetes Mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema
E08.319	Diabetes Mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema
E08.3211-E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema,
E08.3291- E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema,
E08.3311- E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema,
E08.3391- E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema,
E08.3411- E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema,
E08.3491- E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema,
E08.3591- E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema,
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema
E09.3211-E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E09.3291-E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, bilateral
E09.3311-E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E09.3391-E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema,
E09.3411-E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema,
E09.3491-E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E09.3511-E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema
E09.3521-E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E09.3531-E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula



## 7.1 EYLEA (aflibercept) injection- intravitreal injection listed as Group 2 on LCD article

E09.3541-E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E09.3551-E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy
E09.3591-E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E10.3211-E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E10.3291-E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E10.3311-E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E10.3391-E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E10.3411-E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E10.3491-E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E10.35.11-E10.35.13	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E10.35.21-E10.35.23	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E10.35.31-E10.35.33	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E10.35.41-E10.35.43	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E10.35.51-E10.35.53	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy
E10.35.91-E10.35.93	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy without macular edema
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E11.3211-E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E11.3291-E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E11.3311-E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E11.3391-E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema

## 7.1 EYLEA (aflibercept) injection- intravitreal injection listed as Group 2 on LCD article

E11.3411-E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E11.3491-E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E11.3511-E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E11.3521-E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E11.3531-E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula,
E11.3541-E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E11.3551-E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy
E11.3591-E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema
E13.3211- E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E13.3291- E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E13.3311- E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E13.3391- E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E13.3411- E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E13.3491- E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E13.3511- E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema
E13.3521- E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula,
E13.3531- E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E13.3541- E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E13.3551- E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy
E13.3591- E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8111	Central retinal vein occlusion, right eye, with retinal neovascularization

## 7.1 EYLEA (aflibercept) injection- intravitreal injection listed as Group 2 on LCD article

H34.8112	Central retinal vein occlusion, right eye, stable	
H34.8120	Central retinal vein occlusion, left eye, with macular edema	
H34.8121	Central retinal vein occlusion, left eye, with retinal neovascularization	
H34.8122	Central retinal vein occlusion, left eye, stable	
H34.8130	Central retinal vein occlusion, bilateral, with macular edema	
H34.8131	Central retinal vein occlusion, bilateral, with retinal neovascularization	
H34.8132	Central retinal vein occlusion, bilateral, stable	
H34.8310	Tributary (branch) retinal vein occlusion, right eye, with macular edema	
H34.8311	Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization	
H34.8312	Tributary (branch) retinal vein occlusion, right eye, stable	
H34.8320	Tributary (branch) retinal vein occlusion, left eye, with macular edema	
H34.8321	Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization	
H34.8322	Tributary (branch) retinal vein occlusion, left eye, stable	
H34.8330	Tributary (branch) retinal vein occlusion, bilateral, with macular edema	
H34.8331	Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization	
H34.8332	Tributary (branch) retinal vein occlusion, bilateral, stable	
H35.1	Retinopathy of prematurity	
H35.10	Retinopathy of prematurity, unspecified	
H35.101-H35.103	Retinopathy of prematurity, unspecified, (right eye, left eye, bilateral)	
H35.109	Retinopathy of prematurity, unspecified, unspecified eye	
H35.11	Retinopathy of prematurity, stage 0	
H35.111-H35.113	Retinopathy of prematurity, stage 0, (right eye, left eye, bilateral)	
H35.119	Retinopathy of prematurity, stage 0, unspecified eye	
H35.12	Retinopathy of prematurity, stage 1	
H35.121-H35.123	Retinopathy of prematurity, stage 1, (right eye, left eye, bilateral)	
H35.129	Retinopathy of prematurity, stage 1, unspecified eye	Retinop
H35.13	Retinopathy of prematurity, stage 2	
H35.131-H35.133	Retinopathy of prematurity, stage 2, (right eye, left eye, bilateral)	
H35.139	Retinopathy of prematurity, stage 2, unspecified eye	
H35.14	Retinopathy of prematurity, stage 3	
H35.141-H35.143	Retinopathy of prematurity, stage 3, (right eye, left eye, bilateral)	
H35.149	Retinopathy of prematurity, stage 3, unspecified eye	
H35.15	Retinopathy of prematurity, stage 4	Retinop
H35.151-H35.153	Retinopathy of prematurity, stage 4, (right eye, left eye, bilateral)	
H35.159	Retinopathy of prematurity, stage 4, unspecified eye	
H35.16	Retinopathy of prematurity, stage 5	
H35.161-H35.163	Retinopathy of prematurity, stage 5, (right eye, left eye, bilateral)	
H35.169	Retinopathy of prematurity, stage 5, unspecified eye	
H35.3210	Exudative age-related macular degeneration, right eye, stage unspecified	
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization	
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization	

## **7.1 EYLEA (aflibercept) injection- intravitreal injection listed as Group 2 on LCD article**

H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3220	Exudative age-related macular degeneration, left eye, stage unspecified
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3230	Exudative age-related macular degeneration, bilateral, stage unspecified
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar
H35.351-H35.353	Cystoid macular degeneration
H35.81	Retinal edema

## **7.2 EYLEA HD (Aflibercept HD) injection-intravitreal injection listed as Group 5 on LCD**

E08.311	Diabetes Mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema
E08.319	Diabetes Mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema
E08.3211-E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E08.3291- E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E08.3311- E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E08.3391- E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E08.3411- E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E08.3491- E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E08.3511- E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E08.3521- E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula, (right eye, left eye, bilateral)
E08.3531- E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, (right eye, left eye, bilateral)

## 7.2 EYLEA HD (Aflibercept HD) injection-intravitreal injection listed as Group 5 on LCD

E08.3541- E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, (right eye, left eye, bilateral)
E08.3551- E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy, (right eye, left eye, bilateral)
E08.3591- E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema
E09.3211-E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E09.3291-E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E09.3311-E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E09.3391-E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E09.3411-E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E09.3491-E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E09.3511-E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E09.3521-E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, (right eye, left eye, bilateral)
E09.3531-E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, (right eye, left eye, bilateral)
E09.3541-E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, (right eye, left eye, bilateral)
E09.3551-E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy, (right eye, left eye, bilateral)
E09.3591-E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E10.3211-E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)

## 7.2 EYLEA HD (Aflibercept HD) injection-intravitreal injection listed as Group 5 on LCD

E10.3291-E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E10.3311-E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E10.3391-E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E10.3411-E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E10.3491-E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E10.35.11-E10.35.13	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E10.35.21-E10.35.23	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, (right eye, left eye, bilateral)
E10.35.31-E10.35.33	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, (right eye, left eye, bilateral)
E10.35.41-E10.35.43	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, (right eye, left eye, bilateral)
E10.35.51-E10.35.53	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy, (right eye, left eye, bilateral)
E10.35.91-E10.35.93	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E11.3211-E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E11.3291-E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E11.3311-E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E11.3391-E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E11.3411-E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E11.3491-E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E11.3511-E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E11.3521-E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, (right eye, left eye, bilateral)



## 7.2 EYLEA HD (Aflibercept HD) injection-intravitreal injection listed as Group 5 on LCD

E11.3531-E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, (right eye, left eye, bilateral)
E11.3541-E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, (right eye, left eye, bilateral)
E11.3551-E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy, (right eye, left eye, bilateral)
E11.3591-E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema
E13.3211- E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E13.3291- E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E13.3311- E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E13.3391- E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E13.3411- E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E13.3491- E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
E13.3511- E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema, (right eye, left eye, bilateral)
E13.3521- E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula, (right eye, left eye, bilateral)
E13.3531- E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula, (right eye, left eye, bilateral)
E13.3541- E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment, (right eye, left eye, bilateral)
E13.3551- E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy, (right eye, left eye, bilateral)
E13.3591- E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema, (right eye, left eye, bilateral)
H35.3210	Exudative age-related macular degeneration, right eye, stage unspecified
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization

## **7.2 EYLEA HD (Aflibercept HD) injection-intravitreal injection listed as Group 5 on LCD**

H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3220	Exudative age-related macular degeneration, left eye, stage unspecified
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3230	Exudative age-related macular degeneration, bilateral, stage unspecified
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar
H35.351-H35.353	Cystoid macular degeneration, (right eye, left eye, bilateral)
H35.81	Retinal edema

## **7.3 BEOVU (brolucizumab-dbli) injection-intravitreal injection listed as Group 3 on LCD article**

H35.3210	Exudative age-related macular degeneration, right eye, stage unspecified
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization
H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3220	Exudative age-related macular degeneration, left eye, stage unspecified
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3230	Exudative age-related macular degeneration, bilateral, stage unspecified
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar

## **7.4 LUCENTIS (ranibizumab) injection-intravitreal injection & Biosimilars listed as Group 1 on the LCD article**

E08.311	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema
E08.319	Diabetes mellitus due to underlying condition with unspecified diabetic retinopathy without macular edema



#### 7.4 LUCENTIS (ranibizumab) injection-intravitreal injection & Biosimilars listed as Group 1 on the LCD article

E08.3211- E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema
E08.3291- E08.3293	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy without macular edema
E08.3311- E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema
E08.3391- E08.3393	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy without macular edema, bilateral
E08.3411- E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema, bilateral
E08.3491- E08.3493	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy without macular edema
E08.3511- E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema
E08.3521- E08.3523	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment involving the macula,
E08.3531- E08.3533	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E08.3541- E08.3543	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment,
E08.3551- E08.3553	Diabetes mellitus due to underlying condition with stable proliferative diabetic retinopathy
E08.3591- E08.3593	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy without macular edema
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema
E09.319	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy without macular edema
E09.3211-E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema, right eye
E09.3291- E09.3293	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema, right eye
E09.3311- E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E09.3391- E09.3393	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E09.3411- E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema,

#### 7.4 LUCENTIS (ranibizumab) injection-intravitreal injection & Biosimilars listed as Group 1 on the LCD article

E09.3491- E09.3493	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E09.3511- E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema
E09.3521- E09.3523	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E09.3531- E09.3533	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E09.3541- E09.3543	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment,
E09.3551- E09.3553	Drug or chemical induced diabetes mellitus with stable proliferative diabetic retinopathy
E09.3591- E09.3593	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy without macular edema
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E10.319	Type 1 diabetes mellitus with unspecified diabetic retinopathy without macular edema
E10.3211-E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E10.3291-E10.3293	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E10.3311-E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E10.3391-E10.3393	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E10.3411-E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E10.3491-E10.3493	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E10.3511-E10.3513	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E10.3521-E10.3523	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E10.3531-E10.3533	Type 1 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula,
E10.3541-E10.3543	Type 1 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E10.3551-E10.3553	Type 1 diabetes mellitus with stable proliferative diabetic retinopathy
E10.3591-E10.3593	Type 1 diabetes mellitus with proliferative diabetic retinopathy without macular edema
E11.311	Type 2 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E11.319	Type 2 diabetes mellitus with unspecified diabetic retinopathy without macular

#### 7.4 LUCENTIS (ranibizumab) injection-intravitreal injection & Biosimilars listed as Group 1 on the LCD article

	edema
E11.3211- E11.3213	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E11.3291- E11.3293	Type 2 diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E11.3311- E11.3313	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E11.3391- E11.3393	Type 2 diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E11.3411- E11.3413	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E11.3491- E11.3493	Type 2 diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E11.3511- E11.3513	Type 2 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E11.3521- E11.3523	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E11.3531- E11.3533	Type 2 diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E11.3541- E11.3543	Type 2 diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E11.3551- E11.3553	Type 2 diabetes mellitus with stable proliferative diabetic retinopathy
E11.3591- E11.3593	Type 2 diabetes mellitus with proliferative diabetic retinopathy without macular edema
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema
E13.319	Other specified diabetes mellitus with unspecified diabetic retinopathy without macular edema
E13.3211- E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E13.3291- E13.3293	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy without macular edema
E13.3311- E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E13.3391- E13.3393	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy without macular edema
E13.3411- E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E13.3491- E13.3493	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy without macular edema
E13.3511- E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema

#### 7.4 LUCENTIS (ranibizumab) injection-intravitreal injection & Biosimilars listed as Group 1 on the LCD article

E13.3521- E13.3523	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment involving the macula
E13.3531- E13.3533	Other specified diabetes mellitus with proliferative diabetic retinopathy with traction retinal detachment not involving the macula
E13.3541- E13.3543	Other specified diabetes mellitus with proliferative diabetic retinopathy with combined traction retinal detachment and rhegmatogenous retinal detachment
E13.3551- E13.3553	Other specified diabetes mellitus with stable proliferative diabetic retinopathy
E13.3591- E13.3593	Other specified diabetes mellitus with proliferative diabetic retinopathy without macular edema
H34.8110	Central retinal vein occlusion, right eye, with macular edema
H34.8111	Central retinal vein occlusion, right eye, with retinal neovascularization
H34.8112	Central retinal vein occlusion, right eye, stable
H34.8120	Central retinal vein occlusion, left eye, with macular edema
H34.8121	Central retinal vein occlusion, left eye, with retinal neovascularization
H34.8122	Central retinal vein occlusion, left eye, stable
H34.8130	Central retinal vein occlusion, bilateral, with macular edema
H34.8131	Central retinal vein occlusion, bilateral, with retinal neovascularization
H34.8132	Central retinal vein occlusion, bilateral, stable
H34.8310	Tributary (branch) retinal vein occlusion, right eye, with macular edema
H34.8311	Tributary (branch) retinal vein occlusion, right eye, with retinal neovascularization
H34.8312	Tributary (branch) retinal vein occlusion, right eye, stable
H34.8320	Tributary (branch) retinal vein occlusion, left eye, with macular edema
H34.8321	Tributary (branch) retinal vein occlusion, left eye, with retinal neovascularization
H34.8322	Tributary (branch) retinal vein occlusion, left eye, stable
H34.8330	Tributary (branch) retinal vein occlusion, bilateral, with macular edema
H34.8331	Tributary (branch) retinal vein occlusion, bilateral, with retinal neovascularization
H34.8332	Tributary (branch) retinal vein occlusion, bilateral, stable
H35.051-H35.053	Retinal neovascularization, unspecified
H35.3210-H35.3213	Exudative age-related macular degeneration, right eye, (stage unspecified, with active choroidal neovascularization, with inactive scar)
H35.3220-H35.3223	Exudative age-related macular degeneration, left eye, (stage unspecified, with active choroidal neovascularization, with inactive scar)
H35.3230-H35.3233	Exudative age-related macular degeneration, bilateral, (stage unspecified, with active choroidal neovascularization, with inactive scar)
H35.351-H35.353	Cystoid macular degeneration
H35.81	Retinal edema
H44.2A1-H44.2A3	Degenerative myopia with choroidal neovascularization,

## 7.5 VABYSMO (faricimab SVOA) injection-intravitreal injection listed as Group 4 on LCD article

E08.311	Diabetes Mellitus due to underlying condition with unspecified diabetic retinopathy with macular edema
E08.3211-E08.3213	Diabetes mellitus due to underlying condition with mild nonproliferative diabetic retinopathy with macular edema,
E08.3311- E08.3313	Diabetes mellitus due to underlying condition with moderate nonproliferative diabetic retinopathy with macular edema,
E08.3411- E08.3413	Diabetes mellitus due to underlying condition with severe nonproliferative diabetic retinopathy with macular edema,
E08.3511- E08.3513	Diabetes mellitus due to underlying condition with proliferative diabetic retinopathy with macular edema
E09.311	Drug or chemical induced diabetes mellitus with unspecified diabetic retinopathy with macular edema
E09.3211-E09.3213	Drug or chemical induced diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E09.3311-E09.3313	Drug or chemical induced diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E09.3411-E09.3413	Drug or chemical induced diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema,
E09.3511-E09.3513	Drug or chemical induced diabetes mellitus with proliferative diabetic retinopathy with macular edema
E10.311	Type 1 diabetes mellitus with unspecified diabetic retinopathy with macular edema
E10.3211-E10.3213	Type 1 diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E10.3311-E10.3313	Type 1 diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E10.3411-E10.3413	Type 1 diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E10.35.11-E10.35.13	Type 1 diabetes mellitus with proliferative diabetic retinopathy with macular edema
E13.311	Other specified diabetes mellitus with unspecified diabetic retinopathy with macular edema
E13.3211- E13.3213	Other specified diabetes mellitus with mild nonproliferative diabetic retinopathy with macular edema
E13.3311- E13.3313	Other specified diabetes mellitus with moderate nonproliferative diabetic retinopathy with macular edema
E13.3411- E13.3413	Other specified diabetes mellitus with severe nonproliferative diabetic retinopathy with macular edema
E13.3511- E13.3513	Other specified diabetes mellitus with proliferative diabetic retinopathy with macular edema
H34.8110-H34.8112	Central retinal vein occlusion, right eye, (with macular edema, with retinal neovascularization, stable, old central retinal vein occlusion)
H34.8120-H34.8122	Central retinal vein occlusion, left eye, (with macular edema, with retinal neovascularization, stable, old central retinal vein occlusion)
H34.8130-H34.8132	Central retinal vein occlusion, bilateral, (with macular edema, with retinal neovascularization, stable, old central retinal vein occlusion)
H34.8310-H34.8312	Tributary (branch) retinal vein occlusion, right eye, (with macular edema, with retinal neovascularization, stable, old central retinal vein occlusion)
H34.8320-H34.8322	Tributary (branch) retinal vein occlusion, left eye, (with macular edema, with retinal neovascularization, stable, old central retinal vein occlusion)
H34.8330-H34.8333	Tributary (branch) retinal vein occlusion, bilateral, (with macular edema, with retinal neovascularization, stable, old central retinal vein occlusion)
H35.3210	Exudative age-related macular degeneration, right eye, stage unspecified
H35.3211	Exudative age-related macular degeneration, right eye, with active choroidal neovascularization

## 7.5 VABYSMO (faricimab SVOA) injection-intravitreal injection listed as Group 4 on LCD article

H35.3212	Exudative age-related macular degeneration, right eye, with inactive choroidal neovascularization
H35.3213	Exudative age-related macular degeneration, right eye, with inactive scar
H35.3220	Exudative age-related macular degeneration, left eye, stage unspecified
H35.3221	Exudative age-related macular degeneration, left eye, with active choroidal neovascularization
H35.3222	Exudative age-related macular degeneration, left eye, with inactive choroidal neovascularization
H35.3223	Exudative age-related macular degeneration, left eye, with inactive scar
H35.3230	Exudative age-related macular degeneration, bilateral, stage unspecified
H35.3231	Exudative age-related macular degeneration, bilateral, with active choroidal neovascularization
H35.3232	Exudative age-related macular degeneration, bilateral, with inactive choroidal neovascularization
H35.3233	Exudative age-related macular degeneration, bilateral, with inactive scar

## References

Beovu (Brolucizumab). [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; Revised, July 2024.

Eylea (Aflibercept). [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals Incorporated; February 2023. Revised October 2024.

Eylea HD (aflibercept HD). [prescribing information]. Tarrytown, NY: Regeneron Pharmaceuticals Incorporated; December 2023, Revised October 2024.

CGS Administrators, LLC. Local Coverage Article. “(A52451) Billing and Coding: Ranibizumab and biosimilars, Aflibercept, Aflibercept HD, Brolucizumab-dbl and Faricimab-svoa”. Revision date 01/01/2024.

Lucentis (Ranizumab). [prescribing information]. South San Francisco, CA: Genentech Incorporated; March 2018. Accessed online June 20,2023. Revised February 2024.

Vabysmo (faricimab-svoa). [package insert]. South San Francisco, CA: Genentech Incorporated; January 2023. Revised 07/2024.

## Review and Approval Change Log

July 2022	Medical Surgical policy drafted
June 2023	Scope limited to NYS medical surgical prior authorization requirement.
Jan 2024	Reviewed, added aflibercept HD, updated per A52451, R17 on 01/01/24.
May 2024	Reviewed, ICD-10 added to Group 4 (highlighted for approval) per R18 (A52451) On 01/11/2024 CPG updated with note C9161 has deleted and replaced with J0177 per R19 (A52451). Code C9161 remains on the CPG for reference but will be deleted on future copy.
Oct 2024	Reviewed and updated per A52451, R20 updated 09/21//24, added J2779 & 67027, ICD 10 updated per LCD Article listings
Mar 2025	Added Step therapy guidelines
Apr 2025	Healthfirst UM Committee Approval